Astrogen
Latest round
- Series C
Last raised
- Jan 2022
Total raised
- $24M
Investors
- 16
About Astrogen
Astrogen, founded in 2017 in Daegu, South Korea, develops treatments for rare neurological disorders., Ltd. specializes in innovative treatments for rare neurological disorders, particularly for autism spectrum disorder (ASD) and cancer. Its flagship product, AST-001, aims to enhance synaptic pruning to improve ASD symptoms and is undergoing Phase 3 trials in South Korea.1.Astrogen plans to continue developing AST-001 with an expected completion of Phase 3 trials by early 2024, aiming for commercialization shortly thereafter.
Who invested in Astrogen
16 investors across 3 rounds
See all investors in Astrogen
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Astrogen
Who invested in Astrogen?
Astrogen has 16 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Astrogen raised?
Astrogen has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Astrogen last raise money?
Astrogen's most recent round on record is a Series C, in Jan 2022.
What does Astrogen do?
Astrogen, founded in 2017 in Daegu, South Korea, develops treatments for rare neurological disorders.
Where is Astrogen headquartered?
Astrogen is headquartered in Daegu, South Korea.
Which VCs invest in companies like Astrogen?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Astrogen's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Astrogen? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.